中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
19期
2895-2897
,共3页
哮喘%脱敏疗法%布地奈德/福莫特罗粉吸入剂
哮喘%脫敏療法%佈地奈德/福莫特囉粉吸入劑
효천%탈민요법%포지내덕/복막특라분흡입제
Asthma%Desensitization therapy%Symbicort
目的 观察脱敏疗法与布地奈德/福莫特罗粉吸入剂联合用于过敏性支气管哮喘患者的疗效.方法 80例过敏性支气管哮喘患者患者按随机数字表法分为观察组和对照组,每组40例.两组患者均给予常规处理和脱敏疗法,对照组按需给予糖皮质激素,观察组给予布地奈德/福莫特罗粉吸入剂.比较两组肺功能、症状评分和不良反应,并评价疗效.结果 观察组总有效率为92.5％ (37/40),明显高于对照组的72.5％(29/40)(x2=4.76,P＜0.05).两组治疗后1秒钟呼吸容积占预计值的百分比、呼气峰流速值及症状评分均较治疗前明显改善(t=7.92、6.98、5.56、4.42、4.10、4.03,均P＜0.05),观察组改善较对照组更为显著(t=4.83、4.23、4.60,均P＜0.05).观察组不良反应发生率为15.0％ (6/40),明显少于对照组的35.0％ (14/40)(x2=4.20,P＜0.05).结论 脱敏疗法与布地奈德/福莫特罗粉吸入剂联合具有很好的改善哮喘症状和肺功能作用,可使更多患者达到并维持哮喘临床控制,安全性高,值得临床推广应用.
目的 觀察脫敏療法與佈地奈德/福莫特囉粉吸入劑聯閤用于過敏性支氣管哮喘患者的療效.方法 80例過敏性支氣管哮喘患者患者按隨機數字錶法分為觀察組和對照組,每組40例.兩組患者均給予常規處理和脫敏療法,對照組按需給予糖皮質激素,觀察組給予佈地奈德/福莫特囉粉吸入劑.比較兩組肺功能、癥狀評分和不良反應,併評價療效.結果 觀察組總有效率為92.5％ (37/40),明顯高于對照組的72.5％(29/40)(x2=4.76,P＜0.05).兩組治療後1秒鐘呼吸容積佔預計值的百分比、呼氣峰流速值及癥狀評分均較治療前明顯改善(t=7.92、6.98、5.56、4.42、4.10、4.03,均P＜0.05),觀察組改善較對照組更為顯著(t=4.83、4.23、4.60,均P＜0.05).觀察組不良反應髮生率為15.0％ (6/40),明顯少于對照組的35.0％ (14/40)(x2=4.20,P＜0.05).結論 脫敏療法與佈地奈德/福莫特囉粉吸入劑聯閤具有很好的改善哮喘癥狀和肺功能作用,可使更多患者達到併維持哮喘臨床控製,安全性高,值得臨床推廣應用.
목적 관찰탈민요법여포지내덕/복막특라분흡입제연합용우과민성지기관효천환자적료효.방법 80례과민성지기관효천환자환자안수궤수자표법분위관찰조화대조조,매조40례.량조환자균급여상규처리화탈민요법,대조조안수급여당피질격소,관찰조급여포지내덕/복막특라분흡입제.비교량조폐공능、증상평분화불량반응,병평개료효.결과 관찰조총유효솔위92.5％ (37/40),명현고우대조조적72.5％(29/40)(x2=4.76,P＜0.05).량조치료후1초종호흡용적점예계치적백분비、호기봉류속치급증상평분균교치료전명현개선(t=7.92、6.98、5.56、4.42、4.10、4.03,균P＜0.05),관찰조개선교대조조경위현저(t=4.83、4.23、4.60,균P＜0.05).관찰조불량반응발생솔위15.0％ (6/40),명현소우대조조적35.0％ (14/40)(x2=4.20,P＜0.05).결론 탈민요법여포지내덕/복막특라분흡입제연합구유흔호적개선효천증상화폐공능작용,가사경다환자체도병유지효천림상공제,안전성고,치득림상추엄응용.
Objective To investigate the desensitization therapy combined with budesonide/symbicort inhalant for treatment of allergic bronchial asthma.Methods 80 patients with allergic asthma randomly divided into observation group and control group,each group of 40 cases.Two groups were given conventional treatment and desensitization therapy,the control group required glucocorticoid,the observation group received budesonide/symbicort inhalant.were evaluated.Results The total effective rate in the observation group was 92.5％ (37/40),the control group was 72.5％(29/40),the difference was statistically significant (P ＜0.05).FEV1.0％ in the two groups after treatment,PET and symptom score were significantly improved after treatment(P ＜0.05).The observation group improved more significantly than that of the control group (P ＜0.05).The incidence of adverse reaction in observation group was 15％(6/40),significantly less than that in the control group 35％ (14/40),the difference was statistically significant (P ＜0.05).Conclusion Desensitization therapy combined with budesonide/symbicort inhalant in asthma symptoms could improve asthma and lung function,which has high safety and worthy of clinical application.
